Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title and Summary	View
Aug 06, 2020	PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine - Senior Vice President of Corporate and Patient Relations recognized as one of the 100 most inspiring people in the life-sciences industry - SOUTH PLAINFIELD, N.J. , Aug. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate	Additional Formats
Aug 05, 2020	PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update - Strong Emflaza® 2Q 2020 performance with 30% YoY net product revenue increase - - Initiated PTC299 trial in COVID-19 in multiple countries - - Initiated clinical trial with PTC857, identified from Bio-e platform - - Greater than $1B in cash to accelerate pipeline growth - SOUTH PLAINFIELD,	Additional Formats
Jul 22, 2020	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results SOUTH PLAINFIELD, N.J. , July 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company's business and outlook on Wednesday, August 5,	Additional Formats
Jul 21, 2020	PTC Therapeutics to Host Deep Dive Webinar on Splicing Platform SOUTH PLAINFIELD, N.J. , July 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET .	Additional Formats
Jul 20, 2020	PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million - Strategic partnership with Royalty Pharma plc. enables PTC to strengthen and advance its diversified rare disorders portfolio - - Conference call scheduled for 8:30 am ET - SOUTH PLAINFIELD, N.J. , July 20, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.	Additional Formats
Jul 08, 2020	PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857 - First in human trial for PTC857, the second compound in the Bio-e platform to enter clinical trials - SOUTH PLAINFIELD, N.J. , July 8, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the first subject in the Phase 1 clinical trial evaluating PTC857 in healthy	Additional Formats
Jun 29, 2020	PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy - EU label update supports Translarna use in patients who became non-ambulatory while on therapy - SOUTH PLAINFIELD, N.J. , June 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines	Additional Formats
Jun 17, 2020	PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19 - Oral treatment with novel dual-mechanism of action has the potential to address the two critical elements of COVID-19; viral replication and uncontrolled inflammatory response - - Randomized, double-blind, placebo-controlled, multi-national Phase 2/3 clinical study with two stages to initiate	Additional Formats
Jun 12, 2020	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH PLAINFIELD, N.J. , June 12, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 10, 2020 it approved non-statutory stock options to purchase an aggregate of 54,675 shares of its common stock and 3,940 restricted stock units ("RSUs"), each representing the	Additional Formats
Jun 12, 2020	PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy - Risdiplam significantly improved motor function after 24 months of treatment in people aged 2-25 years with type 2 or 3 SMA in SUNFISH Part 1 - - Preliminary 12-month data in the JEWELFISH study in previously treated patients demonstrated increases in SMN protein levels - - Data presented at	Additional Formats